LAWRENCEVILLE, N.J. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the independent Data Monitoring Committee (iDMC) ...
Blinded Progression-Free Survival (PFS) Rate in the OPTIMA Study is Consistent With the Subgroup Patient Population That Showed Benefit in the HEAT Study ThermoDox®-Highlighted Symposium, “Emerging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results